Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ) (HNSBF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
hnsbf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 4 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Hansa Biopharma AB (publ)You HNSBF | $246M | N/A | — | — |
 Cellectis S.A. CMVLF | $251M | N/A | — | -$0.70 |
 Frontage Holdings Corporation FGHQF | $304M | 44.63x | — | $0.00 |
 Mayne Pharma Group Limited MAYNF | $126M | N/A | — | -$1.14 |
 hVIVO plc OPORF | $241M | N/A | — | -$0.01 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Hansa Biopharma AB (publ) (HNSBF) measures how much investors pay for each dollar of the company's trailing earnings. HNSBF's current PE ratio of N/A is calculated by dividing its stock price of $2.90 by its TTM earnings per share of —.
Frequently asked questions
HNSBF pe ratio · 6 questionsHNSBF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.90 and TTM EPS of —. Data sourced from Financial Modeling Prep via HNSBF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Hansa Biopharma AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09